Studies have shown that high ABCB1 mRNA/protein expression was associated with poor clinical outcome and chemoresistance in many cancers, including ovarian cancer[13-16]; However, some studies found no or the opposite relationship[17,18]; (3) ABCB3 was chosen as it is in the same subfamily as ABCB1 and closest in structure to ABCB1 but has not been widely studied in ovarian cancer[7]. This evidence concerns the gene TAP2 and ovarian carcinoma.